262 related articles for article (PubMed ID: 27888104)
1. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
[TBL] [Abstract][Full Text] [Related]
2. Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, independently of PPARγ in human glioma cells.
Lee MW; Kim DS; Kim HR; Kim HJ; Yang JM; Ryu S; Noh YH; Lee SH; Son MH; Jung HL; Yoo KH; Koo HH; Sung KW
Biochem Biophys Res Commun; 2012 Jan; 417(1):552-7. PubMed ID: 22177955
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines.
Yang YC; Tsao YP; Ho TC; Choung IP
Int J Gynecol Cancer; 2007; 17(2):418-25. PubMed ID: 17316361
[TBL] [Abstract][Full Text] [Related]
4. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
6. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Al-Alem L; Southard RC; Kilgore MW; Curry TE
PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
[TBL] [Abstract][Full Text] [Related]
7. [Pro-apoptotic effect of ciglitazone in leukemic HL-60 cells via PPARγ and P38 MAPK signaling pathway].
Liu JJ; Liu WD; Liu XD; Raj-Shrestha P; Liu PQ; Huang HQ; Wu CB; Wang CZ; Xu Y; Xiao RZ; Lin DJ; Huang RW
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(32):2270-4. PubMed ID: 21029675
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
Fujita M; Hasegawa A; Yamamori M; Okamura N
J Exp Clin Cancer Res; 2017 Jul; 36(1):91. PubMed ID: 28673319
[TBL] [Abstract][Full Text] [Related]
9. EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
Chbicheb S; Yao X; Rodeau JL; Salamone S; Boisbrun M; Thiel G; Spohn D; Grillier-Vuissoz I; Chapleur Y; Flament S; Mazerbourg S
Biochem Pharmacol; 2011 May; 81(9):1087-97. PubMed ID: 21338579
[TBL] [Abstract][Full Text] [Related]
10. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death.
Jung JY; Yoo CI; Kim HT; Kwon CH; Park JY; Kim YK
Toxicology; 2007 May; 234(1-2):73-82. PubMed ID: 17363128
[TBL] [Abstract][Full Text] [Related]
11. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells.
Kim SH; Yoo CI; Kim HT; Park JY; Kwon CH; Kim YK
Toxicol Appl Pharmacol; 2006 Sep; 215(2):198-207. PubMed ID: 16616945
[TBL] [Abstract][Full Text] [Related]
12. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
13. [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
Koirala K; Wan YL; Liu YC; Wang X; Cui W; Wang CL; Chen HN; Wang HY; Zhu J
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):385-8. PubMed ID: 16892143
[TBL] [Abstract][Full Text] [Related]
14. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP.
Liu JJ; Guo YW; Fang ZG; Si XN; Wu XY; Liu PQ; Lin DJ; Xiao RZ; Xu Y; Wang CZ; Li XD; He Y; Huang RW
Int J Mol Med; 2009 Nov; 24(5):623-32. PubMed ID: 19787196
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.
Park BH; Lee SB; Stolz DB; Lee YJ; Lee BC
J Biol Chem; 2011 Jun; 286(22):20087-99. PubMed ID: 21467033
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Liu JJ; Liu PQ; Lin DJ; Xiao RZ; Huang M; Li XD; He Y; Huang RW
Ann Hematol; 2007 Mar; 86(3):173-83. PubMed ID: 17089125
[TBL] [Abstract][Full Text] [Related]
18. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
19. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
Fujita M; Yagami T; Fujio M; Tohji C; Takase K; Yamamoto Y; Sawada K; Yamamori M; Okamura N
Cancer Lett; 2011 Dec; 312(2):219-27. PubMed ID: 21903322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
